Home

At the time of recording, Colleen Keenan was a consultant with Advisory Board’s Clinical Innovators Council, a membership group for researchers designed to help suppliers strengthen their relationships with integrated delivery networks and their providers. Colleen had been with Advisory Board for over four years and has worked in several areas, including pharmacy and devices. She recently left Advisory Board to pursue graduate studies.

GenXys, a health tech company focused on pharmacogenetic enhanced prescribing automation software, is pleased to announce that it has closed an oversubscribed seed round at $3 million. Led by Green Shield Canada, (GSC), with key investors including TELUS Ventures, Esplanade Ventures, Nimbus Synergies, and the Business Development Bank of Canada (BDC Capital).

The fantastic Sara Rogers of the American Society of Pharmacovigilance (ASP) and the Pharmacogenetics Access and Reimbursement Coalition (PARC) joined us in an episode of Precision Insights to discuss ASP, PARC, and the STRIPE Collaborative Community, which aims to accelerate the development of personalized medicine practices as a standard of care. She also gave us insight into some of the current issues in reimbursement for pharmacogenetics.

We’ve got an exciting product release to share with you. This enterprise release of our software extends the capability, interoperability, security, and performance of the most robust and most performant pharmacogenetic (PGx) supported precision prescribing platform on the market. Falling into…

When Melissa Badowski came on our podcast, Precision Insights, to talk about her experiences using telehealth, we were very excited to hear about how she uses it to deliver comprehensive medication management, and her tips for delivering telehealth more effectively.

Jared spoke with us on the Precision Insights podcast about telehealth, and how it has been affected by the COVID-19 pandemic, along with his predictions for the future of telehealth. What follows is a summary of the discussion we had with him; the full podcast can be accessed here.

Dr. James Lu co-founded population genomics company Helix in 2015, where he leads the research, regulatory policy and bioinformatics teams. He oversees the teams that develop and validate the science and technology behind Helix’s solution, including Helix’s next generation sequencing lab. Dr. Lu also works with Helix’s partners to design and execute population-scale genomic research initiatives.

GenXys, a health tech company focused on pharmacogenetic enhanced prescribing automation software, is pleased to announce that it has closed an oversubscribed seed round at $3 million. Led by Green Shield Canada, (GSC), with key investors including TELUS Ventures, Esplanade Ventures, Nimbus Synergies, and the Business Development Bank of Canada (BDC Capital).

We spoke to Erik Abel, former Director of Clinical Transformation, Highmark Health about his experiences in making system-level changes in healthcare and how well-designed clinical decision support systems (CDSS) can fit into that change. He started out in pharmacy as a specialist in cardiac surgery and mechanical circulatory support. At the Ohio State University medical center, he worked on some of their first efforts into alternative payment models. They realized that technology was a key component for driving the changes that they wanted to make. Here are some of the highlights from our discussion.

With the industry moving towards personalized prescribing, pharmacists have become the key to successful pharmacogenomics (PGx) implementation. In this episode of the Precision Insights Podcast, Adrijana Kekic, PGx pharmacist and the program director of education, outpatient pharmacy at the Mayo Clinic, delves into the ways in which pharmacists are getting involved in PGx and the role they will play in the future of personalized medicine.